Pluri (PLUR) Capital Expenditures (2010 - 2025)
Pluri (PLUR) posted quarterly Capital Expenditures of $447000.0 for Q4 2025, up 299.11% year-over-year from $112000.0 in Q4 2024, and up 285.34% quarter-over-quarter from $116000.0 in Q3 2025.
Pluri (PLUR) Capital Expenditures (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Capital Expenditures for 16 consecutive years, with $447000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures rose 299.11% year-over-year to $447000.0; the TTM figure through Dec 2025 stood at $1.9 million (up 344.15% YoY), while the FY2025 annual figure was $1.6 million, up 400.93% from the prior year.
- Capital Expenditures rose to $447000.0 in Q4 2025 per PLUR's latest filing, from $116000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $721000.0 in Q2 2025 and bottomed at $10000.0 in Q2 2024.
- Historically, Capital Expenditures has averaged $160600.0 across 5 years, with a median of $100000.0 in 2023.
- Annual changes were most pronounced in 2024 — Capital Expenditures tumbled 89.69% — and 2025, when it jumped 7110.0%.
- Pluri's Capital Expenditures stood at $29000.0 in 2021, then surged by 134.48% to $68000.0 in 2022, then surged by 77.94% to $121000.0 in 2023, then decreased by 7.44% to $112000.0 in 2024, then surged by 299.11% to $447000.0 in 2025.
- Business Quant data shows PLUR's Capital Expenditures at $447000.0 in Q4 2025, $116000.0 in Q3 2025, and $721000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 447,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 447,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Sep 30, 2025 | 116,000.00 |
| Sep 30, 2025 | 116,000.00 |
| Jun 30, 2025 | 721,000.00 |
| Jun 30, 2025 | 721,000.00 |
| Mar 31, 2025 | 577,000.00 |
| Mar 31, 2025 | 577,000.00 |
| Dec 31, 2024 | 112,000.00 |
| Dec 31, 2024 | 112,000.00 |
| Sep 30, 2024 | 208,000.00 |
| Sep 30, 2024 | 208,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Dec 31, 2023 | 121,000.00 |
| Dec 31, 2023 | 121,000.00 |
| Sep 30, 2023 | 103,000.00 |
| Sep 30, 2023 | 103,000.00 |